

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 17, 2021

AVROBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38537
(Commission
File Number)

81-0710585
(I.R.S. Employer
Identification No.)

**One Kendall Square
Building 300, Suite 201
Cambridge, MA 02139**
(Address of principal executive offices, including zip code)

(617) 914-8420
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	AVRO	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On June 17, 2021, AVROBIO, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the slide presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 [AVROBIO, Inc. slide presentation, dated June 2021.](#)

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBR

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVROBIO, INC.

Date: June 17, 2021

By: /s/ Geoff MacKay
Geoff MacKay
President and Chief Executive Officer



AVROBIO

Corporate
Presentation

JUNE 2021

Disclaimer



This presentation has been prepared by AVROBIO, Inc. ("AVROBIO") for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and AVROBIO's own internal estimates and research. While AVROBIO believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and AVROBIO makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. While AVROBIO believes its internal research is reliable, such research has not been verified by any independent source.

This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as "aims," "anticipates," "believes," "could," "designed to," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our current and prospective product candidates; the design, commencement, enrollment and timing of ongoing or planned clinical trials and regulatory pathways; our plans and expectations with respect to the development of our clinical and preclinical product candidates, including timing, design and initiation of our potential clinical and registration trials and anticipated interactions with regulatory agencies; the timing of anticipated clinical and regulatory updates; the timing of patient recruitment and enrollment activities, clinical trial results, and product approvals; the timing and results of our ongoing preclinical studies; the anticipated benefits of our gene therapy platform including the potential impact on our commercialization activities, timing and likelihood of success; the anticipated benefits and safety profile of busulfan as a conditioning agent; the expected benefits and results of our manufacturing technology, including the

implementation of our plato[®] platform in our clinical trials and gene therapy programs; the expected safety profile of our investigational gene therapies; the potential impact of the COVID-19 outbreak on our clinical trial programs and business generally; and the market opportunity for and anticipated commercial activities relating to our investigational gene therapies. Any such statements in this presentation that are not statements of historical fact may be deemed to be forward-looking statements.

Any forward-looking statements in this presentation are based on our current expectations, estimates and projections about our industry as well as management's current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed or commercialized; the risk that regulatory agencies may disagree with our anticipated development approach for our product candidates such as AVR-RD-01, including that we may not be able to utilize our planned registration trial of AVR-RD-01 for full approval but instead be required to conduct additional testing, that we may be required to conduct our planned testing in a more time-consuming, expensive, challenging or otherwise different manner than we envision or have conducted for our existing trials, particularly in light of the FDA's preference for clinical trials to be double-blinded and potentially include sham controls, and the risk that we may not be able to utilize our envisioned surrogate endpoint to support full approval of AVR-RD-01 but instead be required to measure a different endpoint such as a clinical outcome; the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators; the risk that we may not successfully recruit or enroll a sufficient number of patients for our clinical trials; the risk that we may not realize the intended benefits of our gene therapy platform, including the features of our plato[®] platform; the risk that our product candidates or procedures in connection with the administration thereof, including our use of busulfan as a conditioning agent, will not have the safety or efficacy profile that

we anticipate; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving our product candidates; the risk that we will be unable to obtain and maintain regulatory approval for our product candidates; the risk that the size and growth potential of the market for our product candidates will not materialize as expected; risks associated with our dependence on third-party suppliers and manufacturers; risks regarding the accuracy of our estimates of expenses and future revenue; risks relating to our capital requirements and needs for additional financing; risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our development timeline and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises; and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in AVROBIO's most recent Annual or Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO's subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Note regarding trademarks: plato[®] is a registered trademark of AVROBIO. Other trademarks referenced in this presentation are the property of their respective owners.

Copyright © 2021 AVROBIO, Inc. All rights reserved.





Purpose

Freedom from a lifetime
of genetic disease.

Vision

Bring personalized gene
therapy to the world.

Leadership in *ex vivo* lentiviral gene therapy



Leading pipeline for 6 lysosomal disorders

First-in-class gene therapies



Multi-billion dollar market potential

>50,000 target patient population
~\$4.8 billion annual net sales SOC



Industry-leading platform: plato®

Foundation for worldwide commercialization and pipeline expansion

16 Patients dosed across **3** indications

100% of patients out >6 months show **durability**; Longest out **3.5** years

3 Registration trials planned for 2022; Pivoting to commercial readiness

SOC: Standard of Care

AVROBIO POWERED BY plato



Leading lysosomal disorder gene therapy pipeline









Multiple milestones across pipeline expected over the next 12 months

WHOLLY-OWNED	Indication	IND-Enabling	Phase 1/2	Planned Upcoming Milestones
	Fabry AVR-RD-01			1Q22 – Clinical and regulatory update at WORLDSymposium™ Mid22 – Initiate registration trial
	Cystinosis AVR-RD-04			4Q21 – Clinical trial and regulatory update 2H22 – Initiate registration trial
	Gaucher type 1 AVR-RD-02			1H22 – Clinical trial update
	Gaucher type 3 AVR-RD-06			2H22 – Initiate registration trial
	Hunter AVR-RD-05			1H22 – Initiate Phase 1/2 clinical trial
	Pompe AVR-RD-03			1H22 – Initiate Phase 1/2 clinical trial



Multi-billion dollar market opportunity

Pipeline of first-in-class indications targeting > 50,000 patients

Disease	Approx. 2020 Global Net Sales†	Five-Year SOC Cost per U.S. Patient*	Selected Companies w/ Marketed Therapies
Fabry	\$1.4B	\$1.7M	SANOFI GENZYME  
Cystinosis	\$0.2B	\$4.3M	
Gaucher	\$1.5B	\$2.3M	SANOFI GENZYME  
Hunter	\$0.6B	\$2.4M	 
Pompe	\$1.1B	\$3.2M	SANOFI GENZYME 
Total: \$4.8B			


Sources: Rombach S et al., Orphanet J Rare Dis, 2013; van Dussen L et al., Orphanet J Rare Dis, 2014
 * WAC pricing from Redbook using standard dosing assumptions
 † 2020 Net Sales from company annual and other reports
 ‡ Horizon's Procysbi oral therapy (delayed release cysteamine bitartrate); midpoint between avg. adult and pediatric
 Note: Shire acquired by Takeda in 2019
 SOC: Standard of Care




Significant advantages over standard of care

Lifelong treatments vs. potential single-dose therapy

DISEASE PROGRESSION CONTINUES



COULD HALT, PREVENT OR REVERSE DISEASE



Enzyme or protein level	Transient, intermittent elevation	Long-term, continuous elevation
Treatment burden	Bi-weekly IV infusions	Single IV infusion
Ability to impact CNS	No	Yes

ERT: Enzyme Replacement Therapy; IV: Intravenous; HSC: Hematopoietic Stem Cells



Durability demonstrated across clinical programs

First patient out 3.5 years; 10 patients out 1 year or more


PROGRAM	PATIENT	MONTHS POST-INFUSION
Fabry Phase 1	PATIENT 1	42
	PATIENT 2	36
	PATIENT 3	24
	PATIENT 4	24
	PATIENT 5	18
Fabry Phase 2	PATIENT 1	30
	PATIENT 2	18
	PATIENT 3	18
	PATIENT 4	12
	PATIENT 5	0*
	PATIENT 6	0*
	PATIENT 7	0*
Gaucher Type 1 Phase 1/2	PATIENT 1	6
Cystinosis Phase 1/2	PATIENT 1	12
	PATIENT 2	6
	PATIENT 3	1

* Data not yet available




Bu90-TCI conditioning-related side effects have been predictable and transient in first two plato[®] patients

Analysis of 465 non-malignant patients identified optimum exposure for busulfan conditioning*:



Conditioning-related grade 3-4 AEs in first two plato[®] patients



Note: FAB-GT, f-k-a FAB-201, safety data cut-off December 7, 2020; Gaucher safety data cut-off January 4, 2021

* Source: Bartelink IH et al., Lancet Haematol, 2016

Bu90-TCI: Busulfan 90-Target Concentration Intervention; AUC: Area Under the Curve; TCI: Target Concentration Intervention



Fabry disease



Fabry disease opportunity



Tom, living with Fabry disease

Caused by mutation in gene encoding for alpha-galactosidase A enzyme

Standard of care (SOC): ERT

- Not curative, relentless progression of disease continues
- Burdensome and expensive – bi-weekly ERT infusions required; 5-year treatment cost of ERT = ~\$1.7 million*

Unmet needs with SOC:

-  **Kidney function**
Proteinuria, polyuria, kidney failure
-  **Cardiac function**
Left ventricular hypertrophy, fibrosis, heart failure
-  **Neuropathic pain**
Pain and burning sensations in hands and feet, pain crises
-  **Everyday burden of illness, and life expectancy**
Not curative, relentless progression of disease, shortened lifespan
-  **CNS complications**
TIA/stroke, depression, executive function deficit, white matter lesions

Fabry Disease Target Product Profile:**

- Prevents, halts or reverses disease; extends/normalizes lifespan
- Addresses all patient segments – all genetic mutations, male and female, all ages
- Lifelong durability – single infusion; off ERT
- Impacts hard-to-reach organs – e.g., brain, heart, kidney
- Well tolerated

Affects ~ 1:40,000 males and 1:118,000 females in U.S.


* WAC pricing from Redbook using standard dosing assumptions
** Note: these are target attributes for a first-line therapy





Two AVR-RD-01 Fabry clinical trials


12 patients dosed across Phase 1 and 2




PHASE 1

Investigator-Sponsored Trial*

FULLY ENROLLED




OBJECTIVES	PATIENTS
<ul style="list-style-type: none">• Safety and tolerability• Preliminary efficacy	<ul style="list-style-type: none">• n = 5 patients• 18 – 59 year-old males• On ERT >6 months prior to enrollment



PHASE 2

AVROBIO FAB-GT Trial **

ACTIVELY RECRUITING





OBJECTIVES	PATIENTS
<ul style="list-style-type: none">• Safety and tolerability• Efficacy	<ul style="list-style-type: none">• n = 8-12 patients*** (7 dosed to-date)• 16 – 50 year-old males***• Treatment naïve

* Sponsored by FACTs team (Fabry Disease Clinical Research and Therapeutics) in Canada
** FAB-GT aka FAB-201
*** Plan to increase to up to 14 patients with protocol amendment, including females



Clinically meaningful and statistically significant reduction in substrate in first two evaluative kidney biopsies






Two-sample t-test for difference between average PTCs at Baseline vs. 48 weeks; $p < 0.0001$; Error bar represents the standard error at Baseline (n=48 PTCs) and 48 weeks (n=101 PTCs). Scored by 2 independent, blinded pathologists

Two-sample t-test for difference between average PTCs at Baseline vs. 48 weeks; $p < 0.0001$; Error bar represents the standard error at Baseline (n=103 PTCs) and 48 weeks (n=99 PTCs). Scored by 2 independent, blinded pathologists

Baseline: The last available, non-missing observation prior to AVR-RD-01 infusion
 Note: With respect to Fabry disease, Gb3 inclusions per PTC is interchangeable with GL-3 inclusions per KIC
 PTC: Peritubular Capillary; Gb3: Globotriaosylceramide; GL-3: Globotriaosylceramide; KIC: Kidney Interstitial Capillary


Durability demonstrated over multiple measures up to 2.5 years

Patient 4 dosed using plato®





70% average plasma lyso-Gb3 reduction



Reduction from Baseline to Last Observation


Patient 1	86%
Patient 2	N/A
Patient 3	55%
Patient 4	69%

Lyso-Gb3 Plasma Reference Value: 2.4 nM; Lyso-Gb3: Globotriaosylsphingosine
 Note: Patient 2 has normal substrate, consistent with late-onset cardiac variant phenotype



25% average plasma lyso-Gb3 reduction below baseline ERT


All patients who have discontinued ERT remain off ERT*



* As of January 11, 2021
 Lyso-Gb3: Globotriaosylsphingosine; ERT: Enzyme Replacement Therapy; Rx: Therapy



Kidney function (eGFR) stable up to 3.5 years*



* Eight of nine patients stable; other patient entered trial with more advanced kidney disease and a baseline eGFR level <50 mL/min/1.73m²; as expected, this patient has not stabilized, and the patient remains on ERT
 Note: eGFR was calculated using the CKD-EPI formula
 eGFR: Estimated Glomerular Filtration Rate; CKD: Chronic Kidney Disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration




No unexpected safety events identified

Conditioning-related side effects have been manageable and transient

Phase 1 & 2 AEs and SAEs

- No AEs or SAEs related to AVR-RD-01 drug product
- AEs across trials generally consistent with myeloablative conditioning, underlying disease or pre-existing conditions
- Phase 1 AEs (n=94)
 - Grade 3 or 4 (n=14)
- Phase 1 SAEs (n=2) resolved without clinical sequelae
 - Post-AVR-RD-01 treatment: febrile neutropenia; thrombophlebitis
- Phase 2 AEs (n=111)
 - Grade 3 or 4 (n=22)
- Phase 2 SAEs (n=6) resolved without clinical sequelae
 - Post-AVR-RD-01 treatment: dehydration; nausea; vomiting; febrile neutropenia

Phase 2 conditioning-related grade 3/4 AEs



Note: Phase 2 safety data cut-off December 7, 2020; Phase 1 safety data cut-off November 26, 2020
 AE: Adverse Event; Bu: Busulfan; Mel: Melphalan



Cystinosis



Cystinosis opportunity



Jaxon, living with cystinosis

Caused by CTNS gene defect, resulting in cystine buildup in lysosomes

Standard of care (SOC): Cysteamine pills & eye drops

- Not curative, relentless progression of disease continues; significantly shortened lifespan; kidney transplant often required
- Burdensome and expensive – high pill burden and hourly eye drops; 5-year treatment cost with SOC ~\$4.3 million*

Unmet needs with SOC:



Kidney function

Renal Fanconi syndrome, proteinuria, CKD, kidney failure



Vision

Corneal cystine accumulation, photophobia, involuntary eyelid closure



Endocrine disorders

Softening & deformation of bones, hypothyroidism, diabetes, infertility



CNS complications

Myopathy, hypotonia, tremors, swallowing, neurodevelopmental issues



Everyday burden of illness, reduced life expectancy

High pill burden causes GI discomfort; sulfur body odor and breath

Cystinosis Target Product Profile:**

- Prevents, halts or reverses disease; extends/normalizes lifespan
- Addresses all patient segments – male & female; kidney transplant independent; all ages
- Lifelong durability – single infusion; off cysteamine pills and eye drops
- Impacts hard-to-reach organs – e.g., eye, endocrine organs, brain
- Well tolerated

Affects ~ 1:170,000 people

* WAC pricing from Redbook using standard dosing assumptions

** Note: these are target attributes for a first-line therapy




Steady enrollment in AVR-RD-04 IST trial in cystinosis



PHASE 1/2
AVR-RD-04

ACTIVELY RECRUITING:



OBJECTIVES	PATIENTS
<ul style="list-style-type: none">• Safety and tolerability• Hypothesis generation of endpoints	<ul style="list-style-type: none">• Up to 6 patients (3 patients enrolled to-date)• Adults and adolescents• Cohorts 1-2 >18 years; Cohort 3 >14 years• Male and female• Oral and ophthalmic cysteamine

AVR-RD-04 trial sponsored by University of California, San Diego; IST does not use plato® platform
Note: AVR-RD-04 aka CTNS-RD-04
IST: Investigator Sponsored Trial





All patients continue to be cysteamine-independent


CYSTINOSIS	PATIENT	MONTHS OFF CYSTEAMINE PILLS AND EYE DROPS POST AVR-RD-04 INFUSION
OFF cysteamine pills	PATIENT 1	16
	PATIENT 2	6
	PATIENT 3	2
OFF cysteamine eye drops	PATIENT 1	16
	PATIENT 2	5
	PATIENT 3	1

Note: All 3 subjects remain off cysteamine pills and eye drops.
 Subjects 2 and 3 stopped cysteamine eye drops 1-month post-transplant (per protocol).
 Subject 1 stopped cysteamine eye drops prior to baseline.
 Data as of January 20, 2021



eGFR data at 16 months suggest slowing of renal function deterioration post-gene therapy


NEW DATA POINT



Note: These results are for a single patient only and may vary in the study population; eGFR calculated using CKD-EPI formula; eGFR: Estimated Glomerular Filtration Rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration



Sharp drop in the number and size of cystine crystals in skin and rectal biopsies



Note: These results are for a single patient only and may vary in the study population



* Calculation of reduction in average intracytoplasmic crystals per cell in skin biopsy revised based on baseline value of 4.0 (vs. 4.6 as shown in previous presentations)



Substantial decline in corneal crystals observed at 1 year

Front of cornea

Back of cornea



Note: These results are for a single patient only and may vary in the study population; IVCM: In Vivo Confocal Microscopy; OD: Oculus Dexter (right eye); HRT3: Heidelberg Retina Tomograph 3




Photophobia improved meaningfully at 1 year

Photophobia, or extreme sensitivity to light, is a hallmark of cystinosis

Cystinosis photophobia intensity associated with:

- Crystal density (light scattering)
- Inflammatory cell infiltration
- Corneal nerve damage

Self-Assessed Photophobia Grade
(Patient 1)



Liang, H. IONS May 2015



Darker pigmentation may be a sign of multi-functional cystinosin activity post-gene therapy

Cystinosin is located in melanosomes and regulates melanin synthesis

Patient 1 appears to exhibit progressively darkening skin, eyebrows and hair color post-infusion, suggesting a possible impact of cystinosin protein on melanin




Note: These results are for a single patient only and may vary in the study population; Background removed for clarity
Source: Chiaverini et al., FESEB, 2012



VCN trending as expected across patients

Patient 1 reached VCN therapeutic plateau

NEW DATA POINT



* From second apheresis
 VCN: Vector Copy Number; PBCs: Peripheral Blood Cells; dg: Diploid Genome



No unexpected safety events

Conditioning-related side effects have been manageable and transient

No SAEs or AEs related to AVR-RD-04 drug product

AEs & SAEs reported

- AEs (n=53)
 - Majority of AEs are mild or moderate and resolved
- SAE (n=1)
 - Post AVR-RD-04 treatment: appendicitis unrelated to study treatment or procedures
- AEs are generally consistent with myeloablative conditioning or underlying disease:
 - Pre-AVR-RD-04 treatment and prior to conditioning (not all events listed)**
 - Diarrhea, hypokalemia, dizziness
 - Dehydration, vomiting
 - Post-AVR-RD-04 treatment (not all events listed)**
 - Alopecia, intermittent diarrhea, vomiting, loss of appetite
 - Mucositis, intermittent febrile neutropenia, intermittent epistaxis
 - Intermittent blurry vision, intermittent hypokalemia, mucocoeles
 - Thrombocytopenia

Note: Safety database cut as of May 17, 2021
AE: Adverse Event; SAE: Serious Adverse Event

Gaucher type 1



Gaucher disease type 1 opportunity

Adrianna, living with Gaucher disease type 1

Caused by mutation in the gene encoding for glucocerebrosidase (GCase) enzyme

Standard of care (SOC): ERT

- Not curative, relentless progression of disease continues, including bone crisis and fatigue
- Burdensome and expensive – bi-weekly infusions required; 5-year treatment cost with ERT = ~\$2.3 million*

Unmet needs with SOC:



Bone-related manifestations

Skeletal abnormalities, avascular necrosis, osteoporosis



Hemoglobin levels and platelet counts

Anemia, thrombocytopenia, easy bruising, bleeding



Hepatosplenomegaly

Enlarged liver, enlarged spleen



Everyday burden of illness, and life expectancy

Fatigue, pain, lung disease, biweekly infusions, shortened lifespan



CNS complications

Increased risk of GBA-Parkinson's disease

Gaucher Disease Type 1 Target Product Profile:**

- Prevents, halts or reverses disease; extends/normalizes lifespan
- Addresses all patient segments – all GD1 genetic mutations, all ages, male & female
- Lifelong durability – single infusion; off ERT/chaperone therapy
- Impacts hard-to-reach organs – e.g., brain, bone and bone marrow
- Well tolerated

Affects ~ 1:44,000 people worldwide

* WAC pricing from Redbook using standard dosing assumptions

** Note: these are target attributes for a first-line therapy

Guard1: Phase 1/2 study in Gaucher disease type 1



PHASE 1/2

AVR-RD-02

An adaptive, open-label, multinational phase 1/2 study of the safety and efficacy of *ex vivo*, lentiviral vector-mediated gene therapy AVR-RD-02 for patients with Gaucher disease type 1

ACTIVELY RECRUITING:



RECRUITING PLANNED 2021:



OBJECTIVES

- Safety
- Efficacy
- Engraftment

PATIENTS

- Enrollment goal 8-16 patients
- 18-45-year-old males and females
- Have a confirmed diagnosis of GD1 based on:
 - Deficient glucocerebrosidase enzyme activity
 - Clinical features consistent with GD1

Gaucher disease type 1 patients who are:

- ERT-stable for >24 months *or*
- Treatment-naïve *or*
- Have not received ERT or SRT in the last 12 months


GD1: Gaucher Disease Type 1; ERT: Enzyme Replacement Therapy; SRT: Substrate Reduction Therapy



First patient's plasma chitotriosidase levels spike off ERT

Personal history documents response to intermittent and halted ERT use

Chitotriosidase is a marker of inappropriately activated macrophages (Gaucher cells)




Chitotriosidase Plasma Activity Normal Range: 0.0–44.2 µmol/L/h
ERT: Enzyme Replacement Therapy




Key biomarkers below ERT baseline at 6 months

Lyso-Gb1 is a sensitive and specific marker of toxic metabolite accumulation in Gaucher disease



Chitotriosidase is a marker of inappropriately activated macrophages (Gaucher cells)



Baseline taken one month prior to gene therapy which is when ERT is discontinued
 Lyso-Gb1 Plasma Normal Range: 0.5 – 1.2 ng/mL
 Plasma chitotriosidase activity normal range: 0.0 – 44.2 µmol/L/h
 ERT: Enzyme Replacement Therapy




Platelet counts and hemoglobin in normal range at 6 months, despite being off ERT

Platelet Count




Hemoglobin Concentration



Platelet Count Reference Value Adult: 130-400x10⁹/L; Hemoglobin Reference Value: Males: 13.5-17.5 g/dL; Females: 11.5-16.0 g/dL; grey line: local (safety) lab values; pink dots: central (efficacy) lab values; ERT: Enzyme Replacement Therapy



VCN trending as expected at 6 months



VCN, vector copy number; PBL, peripheral blood leukocytes; dg, diploid genome






No unexpected safety events identified in first patient

Conditioning-related side effects have been predictable and transient

AEs (no SAEs reported)


- No AEs or SAEs related to AVR-RD-02 drug product
- AEs generally consistent with myeloablative conditioning, underlying disease or pre-existing conditions
- AEs n=29
 - Grade 3 (n=7)
 - Eye pain, decreased appetite, dehydration, headache, hypophosphatemia, neutropenia, thrombocytopenia
 - Grade 4 (n=2)
 - Leukopenia and neutropenia
- AEs resolved without clinical sequelae

Conditioning-related grade 3/4 AEs



Note: Safety database cut as of January 04, 2021
 AE: Adverse Event; SAE: Serious Adverse Event; G-CSF: Granulocyte Colony Stimulating Factor
 G-CSF 5 µg/kg @ Days 5, 6, 7, 10, 11, and 14 post-infusion of AVR-RD-02
 Bu90-TCI: Busulfan 90-Target Concentration Intervention; GI: Gastrointestinal

Gaucher type 3



Gaucher disease type 3 opportunity



Maddie, living with Gaucher disease Type 3

Subacute neurological form of Gaucher disease characterized by progressive encephalopathy and associated with the systemic manifestations of Gaucher type 1

Standard of care (SOC): ERT

- Not curative, relentless progression of disease continues; utility of ERT minimized by its inability to impact the CNS
- Burdensome and expensive – bi-weekly infusions required; 5-year treatment cost with ERT = ~\$2.3 million*

Unmet needs with SOC:



CNS complications

Seizures, cognitive problems, poor coordination



Bone-related manifestations

Bone crises, bone pain, avascular necrosis



Hemoglobin levels and platelet counts

Anemia, thrombocytopenia, easy bruising, bleeding



Hepatosplenomegaly

Enlarged liver, enlarged spleen



Everyday burden of illness, and life expectancy

Fatigue, pain, shortened lifespan


Gaucher Disease Type 3 Target Product Profile:

- Prevents, halts or reverses disease; normalizes lifespan
- Addresses all patient segments – all genetic mutations, all ages, male & female
- Lifelong durability – single infusion; off ERT/SRT
- Impacts hard-to-reach organs – e.g., brain, bone and bone marrow
- Well tolerated – no ERT-related side effects

* WAC pricing from Redbook using standard dosing assumptions




Lentiviral gene therapy enables global distribution of functional enzyme to brain and bone in preclinical studies



PRECLINICAL DATA

Widespread distribution of GFP+ cells in the mouse brain

Colocalization with microglia marker



IV-dosed animal

■ GFP+ Engrafted Cells ■ DAPI ■ Iba1

GFP: Green Fluorescent Protein; DAPI: 4',6-diamidino-2-phenylindole; Iba1: Ionized Calcium-Binding Adapter Molecule 1; IV: Intravenous



plato[®]

—
AVROBIO's platform for global
gene therapy commercialization


+ Redefines manufacturing
best practices

+ Solves key industry
challenges



Designed to be fully scalable

Common components and automation leveraged across manufacturing



Note: This diagram is for illustrative purposes only



Proprietary tags deliver therapeutic protein into hard-to-reach organs




Figure adapted from Gleitz H et al., EMBO Mol Med, 2018 Fig 3A; *P<0.05, ***P<0.001, ****P<0.0001; LV GT: Lentiviral Gene Therapy



Thank you




Appendix



Patient #4 is first Fabry patient dosed with plato®


FAB-GT 12 month data for patient #4 with plato® vs. patients #1-3





100% clearance of substrate in kidney biopsy at 1 year

Patient dosed using plato®




Baseline: The last available, non-missing observation prior to AVR-RD-01 infusion
 Note: With respect to Fabry disease, Gb3 inclusions per PTC is interchangeable with GL-3 inclusions per KIC
 PTC: Peritubular Capillary; Gb3: Globotriaosylceramide; GL-3: Globotriaosylceramide; KIC: Kidney Interstitial Capillary




Durability demonstrated over multiple measures up to 3.5 years

Plasma AGA Enzyme Activity




Plasma AGA Activity Reference Range: 5.1–9.2 nmol/hr/mL; AGA: α -galactosidase A

Leukocyte AGA Enzyme Activity



Leukocyte AGA Activity Reference Range: 24–56 nmol/hr/mg protein; AGA: α -galactosidase A

Vector Copy Number



Drug Product VCN/dg


Patient 1: 0.7 Patient 2: 1.4
 Patient 3: 0.8 Patient 4: 1.4
 Patient 5: 1.2

VCN: Vector Copy Number; PBL: Peripheral Blood Leukocytes; dg: Diploid Genome





Cardiac function and mass stable across multiple measures up to 1 year



Abbreviations: EF=Ejection Fraction; EDV=End Diastolic Volume; LV=Left Ventricular.
 Error bar represents the standard error of the population mean (n=4).
 *Reference Range Mean Values Male 20-39 yrs; EF: 64.3 ± 4.2%; EDV: 178.6 ± 30.1 mL; CO: 4-8 L/min; LV Mass Index: 67.8 ± 10.7 g/m²
 **Reference Range Mean Values Male 40-49 yrs; EF: 58-75 %; EDV: 117-200 mL; CO: 4-8 L/min; LV Mass Index: 58-91 g/m²


Source: *Alfakih K et al, J Magn Reson Imaging, 2003 ; **Maceira AM et al, J of Cardiovascular Magnetic Resonance, 2006



Reduction of pre-existing anti-ERT drug IgG antibodies

Suggests potential as a therapeutic option independent of pre-existing antibodies

Fabry Disease Phase 1 IgG Antibody Titer



Similar results observed in other studies

San Raffaele Telethon Institute for Gene Therapy (SR-TIGET)

Change in pre-existing antibodies reported for Hurler disease (MPS-1)

- Ex vivo LV gene therapy with conditioning
- n=6
- Evaluable patients (5/6) demonstrated sustained, supraphysiologic blood IDUA activity
- 4/5 prior ERT (rhIDUA) exposure (5-28 months)
- 4/5 pre-existing ERT-induced IgG antibodies
- 6/6 anti-rhIDUA IgGs undetectable 2 months post-gene therapy

Source: Gentner B et al., Blood, 2019
 ERT: Enzyme Replacement Therapy; IgG: Immunoglobulin G; MPS-1: Mucopolysaccharidosis Type 1; IDUA: Iduronidase; SR-TIGET: San Raffaele Telethon Institute for Gene Therapy; LV: Lentiviral; rhIDUA: Recombinant Human alpha-L-Iduronidase



Updated FDA table of surrogate endpoints (as of 3/31/21)



Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure | FDA

Disease or Use	Patient Population	Surrogate endpoint	Type of approval appropriate for	Drug mechanism of action
Diphtheria vaccine (in combination vaccines)	Persons to be immunized against diphtheria	Anti-diphtheria toxoid antibody	Traditional	Induction of immunity
Duchenne muscular dystrophy (DMD)	Patients with DMD who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping	Skeletal muscle dystrophin	Accelerated	Antisense oligonucleotide
Exocrine pancreatic insufficiency	Patients with exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions	Fecal coefficient of fat absorption	Traditional	Combination of porcine-derived lipases, proteases, and amylases
Fabry disease	Patients with confirmed Fabry disease	Complete/near complete clearance of GL-3 inclusions in biopsied renal peritubular capillaries (using the Fabrazyme Scoring System)	Traditional	Enzyme replacement therapy
Fabry disease	Patients with confirmed Fabry disease and amenable GLA gene variants	Reduction of GL-3 inclusions in biopsied renal peritubular capillaries (using the BLISS methodology)	Accelerated	Pharmacological chaperone
Female hypogonadotropic hypogonadism	Infertile women with hypogonadotropic hypogonadism	Follicle size, serum estradiol and progesterone#	Traditional	Gonadotropin
First aid antiseptic; Health care antiseptic; Consumer antiseptic	General public, consumers, and health care professionals	Bacterial count	Traditional and Monograph	Antimicrobial
Gout	Patients with gout	Serum uric acid	Traditional	Xanthine oxidase inhibitor, URAT1 inhibitor, Uricase
Hepatitis A (Hep A) vaccine	Persons to be immunized against Hep A	Anti-Hep A antigen antibody	Traditional	Induction of immunity
Hepatitis B (Hep B) vaccine	Persons to be immunized against Hep B	Anti-Hep B antigen antibody	Traditional	Induction of immunity
Hepatitis B Virus (HBV)	Patients with HBV infection with or without cirrhosis	Undetectable plasma HBV-DNA for indefinite treatment or HBsAg loss for finite treatment	Traditional	Antiviral
Hepatitis C Virus (HCV)	Patients with HCV infection with or without cirrhosis	Sustained viral response (HCV-RNA)	Traditional	Antiviral
Hepatitis D Virus (HDV)	Patients with HDV infection with or without cirrhosis	≥ 2 log reduction in HDV-RNA plus normalization of ALT or HDV below the LLOQ*	Accelerated	Antiviral
Hepatorenal syndrome	Patients with hepatorenal syndrome type 1	Serum creatinine*	Traditional	Mechanism agnostic*
Homozygous sitosterolemia (phytosterolemia)	Patients with homozygous sitosterolemia (phytosterolemia)	Plasma sitosterol and campesterol	Traditional	Dietary cholesterol absorption inhibitor


FDA: Food and Drug Administration

Note: FDA guidance provides that the acceptability of a surrogate endpoint in a particular clinical development program should not be assumed to be appropriate for use in a different program.




Crystal buildup in eye clearly visible before gene therapy

Patient 1 at baseline




Unrivaled commercial-scale platform in plato[®]





Poised to manufacture at scale

Global infrastructure already in place



Note: This diagram is for illustrative purposes only

CMC achievements have defined the plato[®] story

Strategic investment in technology laid the foundation for our manufacturing leadership



Manufacturing

Robust production platform

- Best-in-class LV manufacturing
- Scalable from plasmid to drug product

Global footprint

- In the clinic in multiple jurisdictions

Cost effective

- Intended to address key COGs issues

Analytics

Robust platform analytics

- Best-in-class VCN assay
- First-in-class transduction assay

Deep product characterization

- First-in-class single cell analytics

Potency assay matrix

- Intended to accelerate regulatory approvals